FIELD: chemistry.
SUBSTANCE: present invention relates to novel substituted derivatives of N-(3-benzoylaminophenyl)-4-pyridyl-2-pyrimidine amine of general formula (I), with inhibitory activity towards protein kinase, method of producing said derivatives and pharmaceutical compositions based on the derivatives. In the compound of formula 1 R1 is hydrogen and R2 is NR5R6, or R1 is NR5R6 and R2 is hydrogen; R3 is trifluoromethyl; R4 is lower alkyl; and R5 and R6 are independently hydrogen, lower alkyl, di(lower alkyl)amino-lower alkyl, N-lower alkylpiperidinyl, N-lower alkylpyrrolidinyl, or lower alkyl, or NR5R6 together represent pyrrolidino, piperidino, morpholino, N-lower alkylpiperazino, 1N-imidazolyl, 1H-2-lower alkylimidazolyl, 1H-4-lower alkylimidazolyl or 1H-2,4-di-lower alkylimidazolyl, or a pharmaceutically acceptable salt of such a compound.
EFFECT: compounds can be used in treating diseases related to inhibition of protein kinase activity, such as neoplastic diseases or leukaemia.
13 cl, 21 ex
Title | Year | Author | Number |
---|---|---|---|
TYROSINE KINASE INHIBITORS | 2008 |
|
RU2445309C2 |
THIENO[3,2-d]PYRIMIDINE DERIVATIVES, POSSESSING INHIBITING ACTION WITH RESPECT TO PROTEINKINASE | 2011 |
|
RU2524210C2 |
DIPHENYL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF TREATMENT | 1997 |
|
RU2175319C2 |
DERIVATIVES OF 1-(4-BENZYLPIPERAZIN-1-YL)-3-PHENYLPROPENONE AND THEIR USE, PHARMACEUTICAL COMPOSITION AND METHOD INHIBITING CHEMOKINE RECEPTORS (CCR-1) | 2003 |
|
RU2347782C2 |
MORPHOLINYL PYRIDONES | 2018 |
|
RU2803158C2 |
NOVEL 4-AMINO-N-HYDROXYBENZAMIDES AS HDAC INHIBITORS FOR TREATING CANCER | 2012 |
|
RU2591190C2 |
MODULATORS OF INTEGRATED STRESS SIGNALING PATH | 2017 |
|
RU2769327C2 |
NOVEL COMPOUNDS | 2015 |
|
RU2691389C2 |
2-CYANOPYRIMIDINE-4-YL CARBAMATE, OR A UREA DERIVATIVE, OR ITS SALT AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2019 |
|
RU2788740C2 |
DERIVATIVES OF QUINAZOLINE | 2002 |
|
RU2302244C2 |
Authors
Dates
2010-01-10—Published
2003-09-26—Filed